Brief: Immutep Reaches Enrolment Target For INSIGHT-003 Trial In 1st Line NSCLC

Immutep

06/02/2023 13:48

Feb 6 (Reuters) - Immutep Ltd  IMM.AX :
    * IMMUTEP REACHES ENROLMENT TARGET FOR INSIGHT-003 TRIAL IN
1ST
LINE NSCLC
    * IMMUTEP LTD - ADDITIONAL DATA IS EXPECTED THROUGHOUT
CALENDAR
YEAR 2023 AND WILL FURTHER INFORM OUR NEXT STEPS IN 1L NSCLC
    * IMMUTEP LTD - PROMISING INITIAL EFFICACY RESULTS SHOWING A
72.7%
RESPONSE RATE AND 90.9% DISEASE CONTROL RATE REPORTED AT SITC
2022

Source text for Eikon:  ID:nGNX53MnxV 
Further company coverage:  IMM.AX